The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, shares the final report of a Phase II study (NCT04273139) of ibrutinib and venetoclax in previously untreated Waldenström’s macroglobulinemia (WM). Dr Castillo highlights that the study was stopped early, and the final analysis shows a median time to progression of three years. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
